Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy

NCT ID: NCT00688038

Last Updated: 2017-09-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-13

Study Completion Date

2017-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical research study is to learn how well magnetic resonance thermal imaging (MRTI) can check the amount of tumor being destroyed using a therapy called laser ablation (a procedure that uses lasers to create heat that is designed to destroy cancer cells).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Laser ablation is designed to destroy tumor tissue with the use of fiber optics that are placed directly into the tumor to deliver laser light energy into the tissue.

In this study, tumor destruction will be checked using MRTI. MRTI is very similar to other MRI techniques, but instead of providing imaging data, MRTI will provide temperature data for cancerous areas in the body during the laser ablation process. If tumor temperature can be measured more accurately, the laser ablation process may be safer.

Laser Ablation and the MRTI Scan:

If you are found to be eligible to take part in this study, on the day you have laser ablation, you will have an intravenous (IV) line placed. You will receive sedation or general anaesthesia (drugs to make you sleep) through a needle in your vein over 1-3 hours to lessen any pain you may have during the procedure. This process will be explained to you.

After receiving the anaesthesia, the following tests and procedures will be performed:

* You will have a limited MRI.
* Your skin will be cleaned and covered with sterile towels and sheets to lower the chance of an infection.
* The doctor will use MRI scans to place a special needle (applicator) into the tumor. This applicator will be used to create heat at a high enough temperature that cells can be destroyed. Small masses may be destroyed in 1 treatment, but larger masses may require that the needle is placed several times. Each heating cycle takes less than 10 minutes.
* During laser ablation, MRTI will be used to monitor the temperature within the ablation zone. The MRTI process is very similar to regular MRI.
* Your heart rate and blood pressure will be measured during the entire procedure.
* The entire procedure may take about 1-3 hours, depending on the size and location of your tumor.

After the procedure is completed, you will be kept in the hospital for 4-6 hours for observation. You will be checked for recovery from the sedation that you received during the procedure. Once you have recovered from the procedure, you will be allowed to leave the hospital. If you have side effects from the procedure, the doctor may decide to keep you in the hospital for a longer time period for observation.

Follow-Up Visits:

After you have completed the procedure, you will return to M. D. Anderson for follow-up visits. About one (1) week after the laser ablation, you will have a physical exam and an X-ray. About one (1) month after the laser ablation, you will have a physical exam and a limited MRI to check the status of the disease.

Length of Study:

You will be considered off-study after the 1-month follow up visit.

This is an investigational study. The laser ablation procedure is an FDA-approved procedure. The devices are commercially available and can be used outside research studies. The investigational part of this study involves using MRTI to check the effect of ablation on the tumor. Up to 24 participants will be enrolled in this study. All will be enrolled at M.D. Anderson.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer Bone Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Laser Ablation + MRTI

Magnetic resonance thermal imaging = MRTI

Group Type EXPERIMENTAL

Laser Ablation

Intervention Type PROCEDURE

Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.

Magnetic Resonance Thermal Imaging

Intervention Type PROCEDURE

MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laser Ablation

Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.

Intervention Type PROCEDURE

Magnetic Resonance Thermal Imaging

MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MRTI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with tumor metastases to the skeleton who are referred to interventional radiology for percutaneous ablation
2. Surgery is not a viable or desirable alternative therapy at the time of enrollment
3. Radiation therapy has failed or not indicated or can be safely postponed
4. Symptomatic or asymptomatic tumor size less than or equal to 3 cm in its largest diameter.
5. Performance status is Eastern Cooperative Oncology Group 2 or better in adults
6. Patient is able to undergo MRI
7. Patients at least 18 years of age

Exclusion Criteria

1. Patients with uncorrectable coagulopathy
2. Patients with pacemaker or defibrillator
3. Patients with metallic prosthesis at the site of the intended ablation
4. Patients with spinal cord compression or epidural tumor extension
5. Patients with vertebral body metastases exhibiting posterior wall destruction
6. Patients with any soft tissue extension of a vertebral tumor
7. Patients with any metastasis that is extrinsically located in vertebra or any long bones of the extremities compromising the cortex
8. Patients with tumors having direct extension or involvement of a joint capsule or a major nerve
9. Patients with Neutropenia (ANC less then 1000) or known active infection
10. Patients unable to undergo conscious sedation
11. Children under 18 years of age will be excluded from this study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioTex, Inc.

INDUSTRY

Sponsor Role collaborator

M.D. Anderson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kamran Ahrar, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mdanderson.org

University of Texas MD Anderson Cancer Center Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2011-00518

Identifier Type: REGISTRY

Identifier Source: secondary_id

2007-0393

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.